In the last trading session, 1.51 million shares of the Atara Biotherapeutics Inc (NASDAQ:ATRA) were traded, and its beta was 0.71. Most recently the company’s share price was $0.73, and it changed around $0.0 or 0.37% from the last close, which brings the market valuation of the company to $86.86M. ATRA currently trades at a discount to its 52-week high of $3.08, offering almost -321.92% off that amount. The share price’s 52-week low was $0.20, which indicates that the current value has risen by an impressive 72.6% since then. We note from Atara Biotherapeutics Inc’s average daily trading volume that its 10-day average is 1.35 million shares, with the 3-month average coming to 3.14 million.
Atara Biotherapeutics Inc stock received a consensus recommendation rating of Overweight, based on a mean score of 2.60. If we narrow it down even further, the data shows that 0 out of 6 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 1 recommended ATRA as a Hold, whereas 1 deemed it a Buy, and 1 rated it as Underweight. Atara Biotherapeutics Inc is expected to report earnings per share of -$0.32 for the current quarter.
Atara Biotherapeutics Inc (NASDAQ:ATRA) trade information
Instantly ATRA has showed a green trend with a performance of 0.37% at the end of last trading. The performance over the last five days has remained in the green territory. The company’s shares are currently up 41.91% year-to-date, but still up 8.63% over the last five days. On the other hand, Atara Biotherapeutics Inc (NASDAQ:ATRA) is -5.58% down in the 30-day period. We can see from the shorts that 11.03 million shares have been sold at a short interest cover period of 4.32 day(s).
The consensus price target as assigned by Wall Street analysts is $3, which translates to bulls needing to increase their stock price by 75.67% from its current value. Analyst projections state that ATRA is forecast to be at a low of $3 and a high of $3.
Atara Biotherapeutics Inc (ATRA) estimates and forecasts
Atara Biotherapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -50.83 percent over the past six months and at a 19.92% annual growth rate that is well above the industry average of 13.60%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 55.60% in revenue this quarter, and will report an increase of 61.80% in the next quarter. The year-over-year growth rate is expected to be 965.20%, up from the previous year.
Consensus estimates provided by 4 financial analysts predict the company will bring in an average of $21.92 million in revenue for the current quarter. 4 analysts expect Atara Biotherapeutics Inc to make $24.68 million in revenue for the quarter ending Jun 2024. The company’s sales for the same quarters a year ago were $1.23 million and $3.77 million respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 1,687.90%. Forecasts for the next quarter put sales growth at 554.60%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 13.12%.
ATRA Dividends
Atara Biotherapeutics Inc’s next quarterly earnings report is expected to be released around May 06 and May 10.
Atara Biotherapeutics Inc (NASDAQ:ATRA)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 6.35% of Atara Biotherapeutics Inc shares, and 73.73% of them are in the hands of institutional investors. The stock currently has a share float of 78.73%. Atara Biotherapeutics Inc stock is held by 132 institutions, with Baupost Group, Inc,.(The) LLC being the largest institutional investor. By Jun 29, 2023, it held 9.67% of the shares, which is about 9.77 million shares worth $15.74 million.
Wasatch Advisors LP, with 8.19% or 8.28 million shares worth $13.34 million as of Jun 29, 2023, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and JP Morgan Small Cap Growth Fund were the top two Mutual Funds as of Jun 29, 2023. The former held 2.71 million shares worth $4.36 million, making up 2.68% of all outstanding shares. On the other hand, JP Morgan Small Cap Growth Fund held roughly 2.46 million shares worth around $3.96 million, which represents about 2.43% of the total shares outstanding.
